Duration of adverse reactions and safe handling methods of Tazetostat (Taveco)

Tazemetostat (Tazemetostat) is a selective EZH2 inhibitor. Adverse reactions are common when treating certain lymphomas and solid tumors, but most are mild to moderate and can be alleviated through monitoring and symptomatic treatment. Clinical data show that common adverse reactions of tazerestat include fatigue, nausea, loss of appetite, thrombocytopenia, anemia and abnormal liver function indicators. These adverse reactions generally appear in the early stages of medication, and most patients' symptoms will be relieved or stabilized after continuing treatment for a few weeks.

For fatigue and mild gastrointestinal reactions (such as nausea, vomiting, loss of appetite), there is usually no need to discontinue medication. Symptoms can be relieved by adjusting daily routine, eating small amounts more often, and using anti-nausea drugs when necessary. Such adverse reactions usually gradually resolve after 1-2 cycles of medication and do not affect the feasibility of long-term treatment. Patients should maintain adequate rest and nutritional intake while taking the medication, and regularly review blood routine and liver function indicators.

Hematological abnormalities are adverse reactions that need to be monitored closely during tazerestat treatment. Some patients may experience a decrease in platelets, white blood cells, or red blood cells. If moderate or above hematological abnormalities occur, the doctor may recommend temporarily stopping the medication or adjusting the dose, and then resume medication based on the recovery of the patient's blood picture. Typically, hematologic abnormalities resolve within days to weeks after discontinuation or dose reduction, and patients should avoid self-adjustment of dosage.

The increase in liver function indicators is also one of the common adverse reactions of tazerestat, especially the increase in ALT and AST. For mild liver function abnormalities, it is usually recommended to continue observation and regular reexamination; for moderate to severe abnormalities, medication needs to be suspended, and the resumption of treatment or dose reduction will be considered after the liver function returns to a safe range. In general, most of the adverse reactions of tazerestat are controllable. Through regular monitoring, timely dosage adjustment and symptomatic treatment, patients can still maintain good drug safety during treatment.

Reference materials:https://www.drugs.com/